{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:32:45Z","timestamp":1778236365603,"version":"3.51.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Aripiprazole is regarded as the first-line antipsychotic medication. Long-term aripiprazole therapy can cause hypoprolactinemia, which may result from its activity as a dopamine agonist. However, there is little information on hypoprolactinemia and steady-state aripiprazole concentrations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The subjects included 66 male and 177 female patients diagnosed with schizophrenia who were treated with aripiprazole. The plasma concentrations of aripiprazole and dehydroaripiprazole and the plasma concentration of prolactin were measured using high-performance liquid chromatography and enzyme immunoassay, respectively. A prolactin concentration of &lt;5 ng\/mL was defined as hypoprolactinemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty-two of the 66 male patients (79%) and 58 of the 177 female patients (33%) had hypoprolactinemia. There were significant inverse correlations between plasma prolactin levels and plasma concentrations of aripiprazole (r<jats:sub>s<\/jats:sub> = \u22120.447, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and the active moiety (aripiprazole plus dehydroaripiprazole) (r<jats:sub>s<\/jats:sub> = \u22120.429, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) in men. In women, significant inverse correlations were also found between plasma prolactin levels and plasma concentrations of aripiprazole (r<jats:sub>s<\/jats:sub> = \u22120.273, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01) and the active moiety (r<jats:sub>s<\/jats:sub> = \u22120.275, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These findings suggest that lower prolactin levels are, to some extent, associated with higher plasma drug concentrations in male and female patients with schizophrenia treated with aripiprazole.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000843","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T22:32:40Z","timestamp":1606257160000},"page":"589-592","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Relationship of Prolactin Concentrations to Steady-State Plasma Concentrations of Aripiprazole in Patients With Schizophrenia"],"prefix":"10.1097","volume":"43","author":[{"given":"Minami","family":"Tasaki","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"},{"name":"Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saaya","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Shinozaki","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/001857870303800308","article-title":"Aripiprazole","volume":"38","author":"Cada","year":"2003","journal-title":"Hosp Pharm."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebocontrolled trials","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori","year":"2010","journal-title":"J Clin Psychopharmacol."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JCP.0000000000001158","article-title":"Lower prolactin levels in patients treated with aripiprazole regardless of antipsychotic monopharmacy or polypharmacy","volume":"40","author":"Sugai","year":"2020","journal-title":"J Clin Psychopharmacol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","article-title":"Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status","volume":"76","author":"Tveito","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/FTD.0b013e3182031021","article-title":"Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia","volume":"33","author":"Suzuki","year":"2011","journal-title":"Ther Drug Monit."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bcpt.12960","article-title":"Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers","volume":"122","author":"Belmonte","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.ftd.0000249944.42859.bf","article-title":"Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients","volume":"28","author":"Molden","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JCP.0000000000000527","article-title":"Aripiprazole-associated hypoprolactinemia in the clinical setting","volume":"36","author":"Sogawa","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1002\/jssc.201000457","article-title":"A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies","volume":"33","author":"Akamine","year":"2010","journal-title":"J Sep Sci."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","article-title":"Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction","volume":"6","author":"Corona","year":"2009","journal-title":"J Sex Med."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","article-title":"Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study","volume":"165","author":"Gr\u00fcnder","year":"2008","journal-title":"Am J Psychiatry."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"18l02303","DOI":"10.4088\/PCC.18l02303","article-title":"A case of decreased milk production associated with aripiprazole","volume":"20","author":"Yskes","year":"2018","journal-title":"Prim Care Companion CNS Disord."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jad.2017.12.021","article-title":"Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice","volume":"228","author":"Cuomo","year":"2018","journal-title":"J Affect Disord."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole","volume":"31","author":"Waade","year":"2009","journal-title":"Ther Drug Monit."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.pnpbp.2009.11.022","article-title":"Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics","volume":"34","author":"Fujii","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"109804","DOI":"10.1016\/j.pnpbp.2019.109804","article-title":"Sexual dysfunctions in schizophrenia: beyond antipsychotics. A systematic review","volume":"98","author":"Dumontaud","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:23:53Z","timestamp":1748971433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000843","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"2020-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}